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Abstract:- 
Background : Psoriasis is a chronic immune-inflammatory-mediated disease characterized by epidermal 
hyperplasia and angiogenesis. Recently, vascular endothelial growth factor receptors (VEGFRs, including 
VEGFR-1, VEGFR-2 and VEGFR-3) were found to be expressed in normal human epidermis and associated 
with proliferation and migration of keratinocytes.  
Objective: The purpose of this study is to investigate the serum level of vascular endothelial growth factor 
receptors (sVEGFR1 and sVEGFR2) in psoriatic patients  
Methods: 100 consenting psoriatic patients(males and females) aged 20-60 years who attended out patients 
clinic of dermatology in Al-Sadr Medical City in AL-Najaf city -Iraq. Psoriasis area and severity index 
assessment was done for each patient. Blood samples was collected for vascular endothelial growth factor 
receptor 1 and receptor 2 measurement. 
Result: The serum level of vascular endothelial growth factor receptor 1 in addition to receptor 2 were 
significantly increased in all group of psoriatic patients compared to healthy controls (P<0.001) .   
Conclusion: The serum level of vascular endothelial growth factor receptor 1 in addition to receptor 2 had 
significant role in evolution of psoriatic plaque.   
Keywords: Serum vascular endothelial growth receptor 1, Serum vascular endothelial growth receptor 
2,Psoriasis area and severity index, Psoriasis.  
List of abbreviation: sVEGFR= serum vascular endothelial growth receptor, PASI = Psoriasis area and severity 
index, SD=standard deviation , ECs=endothelial cells. ELISA= Enzyme Linked Immuno Linked Sorbant Assay. 
 
 
Introduction 
       Psoriasis is a chronic inflammatory skin disease characterized by epidermal hyperplasia, impaired epidermal 
differentiation, and accumulation of distinct leukocyte subpopulations. Although the precise cause of psoriasis is 
indistinct, psoriasis may be the consequence of two main mechanisms: a polygenic inheritance that comprises 36 
chromosomal susceptibility loci, and the other, a strong immunological component(1). New researches have 
been identified that the hyperproliferation and altered differentiations of keratinocytes that occurred in psoriasis 
may link the pathways of angiogenesis and inflammation. Vessels expansion looks to show a significant role in 
the development of psoriatic plaques (2). 
   Vascular endothelial growth factor is a chief factor of neoangiogenesis (3). The influence of VEGF is 
intermediated by VEGF receptors (VEGFRs, comprising VEGFR-1,VEGFR-2 which are principally expresses 
by vascular endothelial cells (ECs)). Vascular endothelial growth factor attaching one of the receptor results in 
receptors stimulation and intracellular signals transductions (4). There are inadequate information about the 
probable role of soluble VEGF receptors in psoriasis (5) 
   The psoriatic lesion is distinguished by sharply marginated erythematous plaque with a white silvery scale that 
spread in a roughly symmetrical fashion on the trunk and limbs (6).                                                                                                            
     When scales are entirely scrapped off, the basement membrane is exposed and perceived as a red moist 
surface (Membrane of Bulkeley), through which dilated capillaries are noticed as red spots. Characteristically, 
the amplified vascularization could be confirmed clinically, by “Auspitz sign” wherever rubbing scales of 
psoriatic plaque result in pinpoint bleedings. On the other hand, Auspitz sign is not sensitive or specific for 
psoriasis (7).  The objective of  study is to evaluate serum level of vascular endothelial growth factor receptors 
(sVEGFR1 and sVEGFR2) in psoriatic patients . 
Materials and Methods 
This is a case-control study which included 150 subjects (100 patients and 50 controls) who attended 
who attended out patients clinic of dermatology in Al-Sadr Medical City in AL-Najaf city –Iraq from 
November/2013 to January /2015. Informed consents were gained from participant.  
The inclusion criteria include, consenting, patients having chronic plaque psoriasis with PASI score > 
20 aged between 20 to 60 years with no co morbid illness or any medications. The groups of the patients are as 
the following:-  
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1- Group I: Includes 20 males whose age ranged from 20 to 39 years . 
2- Group II: Includes 33 females whose age ranged from 20 to 39 years old . 
3- Group III: : Includes 23 males whose age ranged from 40 to 60 years . 
4- Group IV: Includes 24 females whose age ranged from 40 to 60 years old . 
     After informed written consent, Psoriasis Area Severity Index (PASI) scoring was estimated (8). 
A uniformed cases sheets were assigned for every participant in the study which includes: 
1. Age of the patient. 
2. Gender  of the patient. 
3. Disease duration. 
 
sVEGFR1 and sVEGFR2 measurements: Ten milliliters of blood were collected in plane tube without 
anticoagulants , the tubes were left for 30 minute at room temperatures. After coagulation, tubes were centrifuge 
at 1000 rpm for about 15 minutes and then kept at (–20 C) till usage time. Serum aliquots were obtained to 
measure sVEGFR1 and sVEGFR2 by sensitive Enzyme Linked Immuno Linked Sorbant Assay technique 
(ELISA) using ABCAM  Human sVEGFR1 and sVEGFR2 ELISA Kits (9). 
Statistical Analysis:- 
     Statisticalcanalysis were done by SPSS 20.0 (SPSS Inc, Chicago, I L, U S A). 
      The normal distribution was confirmed for all analyzed measures. For correlation analysis, independent t-test 
is utilized to evaluate difference between two group in continuous variable (10). 
Results 
     Of 100 patients included in the study ,43(43%) males and 57 (57%) females. The males to females ratio was 
1:1.3. The patients presented severe form of disease as revealed by psoriasis areas and severity index (PASI) 
score (mean ±SD) of 35.85 ± 9.45 with range (20.76-51.97). 
Serum level of vascular endothelial growth factor receptor 1 (sVEGFR1): 
    The serum vascular endothelial growth receptor 1 showed significant increment in all groups of psoriatic 
patients when compared to the healthy controls(P<0.001). For males and females in the age group 20-39years, 
the P values were 0.0001 and 0.00021 respectively while in age group 40-60years, the P values are 0.00013and 
0.00011for males and females respectively (figure1and figure 2).  
 
Figure 1: vascular endothelial growth factor receptor1 for males and females with age group between 20-
39years (groups I and II). 
sVEGF : serum vascular endothelial growth factor. 
***   significant differences at P<0.001. 
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Figure 2: vascular endothelial growth factor receptor1 for males and females with age group between 40-
60years (groups III and IV). 
sVEGF : serum vascular endothelial growth factor. 
***   significant differences at P<0.001. 
Serum level of vascular, endothelial growth factor receptor2 :- 
     The serum vascular endothelial growth receptor 2 displayed significant increment in all groups of psoriatic 
patients when compared to the healthy controls(P<0.001). For males and females in the age group 20-39years, 
the P values were 0.00024 and 0.0001 respectively while age group 40-60years, the P values are 0.0005and 
0.0002for males and females respectively (figure3and figure 4). 
 
Figure (3): Vascular endothelial growth factor receptor2 for males and females with age group between 
20-39years (groups I and II). 
***  significant differences at P<0.001. sVEGF : serum vascular endothelial growth factor. 
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Figure (4): Vascular endothelial growth factor receptor2 for males and females with age group between 
40-60years(groups III and IV). 
***  significant differences at P<0.001. sVEGF : serum vascular endothelial growth factor  
Discussion 
     The present study showed a slightly female predominance (male/ female ratio approximately 1:1.3) which yet 
again may reflect a sex related preference in psoriatic patients (figure 4.1). This was in accordance to Mallbris et 
al., (2005) who found a female dominance (approaching 1.3:1) as compared with the male. 
       Several researcher reported that psoriasis occurs in any gender or race with equal amount of male and 
female (Smith et al .,1993 and Kerkhof, 2003). There is remaining controversy regarding psoriasis gender 
preponderance and it lies between no difference (Chandaran & Raychaudhuri , 2010) to male preponderance 
(Raychaudhuri & Farber, 2001). In one research, no gender difference were observed in the frequency of items 
related to appearance and socialization (Gupta and Gupta, 1995). 
     Psoriasis can manifest at any age from infancy to old age (Langely et al ., 2011). More than 50% of the 
patients experienced their reportedonset before the age of 40 years(Naldi and Gambini, 2007). Accurate 
determination of the age of onset of psoriasis is problematic as studies, which do so typically rely on a patient's 
recall of the onset of the lesion or determine the onset from the physician's diagnosis as recorded on the initial 
visit. Data based on patient's recall can be inaccurate; determining onset based on first visit to the physician 
could under estimate the time of disease occurrence, as minimal disease may be present for years before a 
consultation is sought (Ferrandiz et al ., 2002and Naldi , 2004). In this study, psoriasis was found to be higher in 
patients of age groups 20-39 years old; the number of the patients in this age group 53/100(53%) as shown in 
figure 4.2 . This result corresponds to an Iraqi study which mentioned that psoriasis was higher in individuals of 
age group 18-40 years old (62.8%) (Lafi et al ., 2010). This finding was also in accordance with what was 
detected by Hwerta and his coworkers (2007) and Zieve and his co-workers (2008) who recognized that the 
highest incidence of psoriasis was in the second decade or in the reproductive age group. On the other hand, 
present result disagree with the finding of Abdullah and his co-workers (2007) who reported that psoriasis 
particularly psoriasis vulgaris was higher and common in individual within 40-50 years old.  
In the present study the youngest patient was 20 years old and oldest was 60 years old.  
       Papp and his co-workers (2011) also found the prevalence of psoriasis was developed in older Canadian 
population ( more than 70 years). While, Bell and his co-workers (1991) revealed that psoriasis tend to appear at 
an earlier age among females than males. 
       Concerning sVEGFR1, our  results suggest that there is highly significant increment in sVEGFR1 in all 
psoriatic patients compared to control (figure 1 and figure 2). 
      Our results are in agreement with the finding of Flisiak and his coworkers (2010) and Flisiak and his 
coworkers (2012) who reported that the increase of serum VEGFR1 becomes significant only in patients with 
severe psoriasis(12,13). 
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     Young et al (2004) also found that in psoriatic patients, the serum VEGF are significantly increased in 
addition to serum circulating (soluble) VEGFR-1, although no direct correlation with disease severity as 
measured by the PASI score was found in this study (14).  
     Additionally, our results suggest that there is highly significant increment in sVEGFR2 in all psoriatic 
patients compared to controls (figure 3 and figure 4). Our finding disagree with Flisiak and his coworkers (2010) 
and Flisiak and his coworkers (2012)  who did not find significant differences in VEGFR2 levels between 
psoriatic patients and controls (12,13). Up to our knowledge no study presents till now supports our result 
regarding sVEGFR2 apart from experimental study done by Man et al., (2008) and Zhou et al.,  (2013) who 
measure epidermal VEGFR1 and VEGFR2 and they discovered that VEGFR1 and VEGFR2 were established to 
be overexpressed by epidermal psoriatic skin compared to controls, supporting their pathological importance in 
the development of psoriatic lesion. These results provide another prospective to understand the mechanism of  
VEGF and VEGFR in psoriasis. That is to say, VEGF participates in the pathogenesis of psoriasis through two 
manners. One is that keratinocytes-derived VEGF induces angiogenesis to provide essential nutriments, energy, 
and cells to support the hyperproliferation of epidermis in a paracrine manner indirectly; the other one is that 
VEGF directly stimulates the proliferation of keratinocytes via VEGFRs expressed on epidermis in an autocrine 
manner(15,16). 
       Remarkably adequate, hypoxias and anoxidative stress likewise occurred in psoriasis lesions , that could be 
linked to over-expression of vascular endothelial growth factor receptors and consequent hyperprofileration of 
epidermal layers(17,18).  
       Bhusanet al., (1999)  established that vascular endothelial growth factors and it's receptors are upregulated 
by keratinocytis of the supra basal epidermal layer and fibroblasts, indicating a dermally resulting impact on 
neoangiogenesis(19).  
      Yang et al (2006) and Man et al ( 2009) revealed that the proliferations of keratinocytes can be stimulated via 
VEGF/VEGFRs pathways and management with aVEGFR tyrosine kinases inhibitors can impede chronic or 
acute skin inflammations like that of psoriasis (20,21). 
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